{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "decreases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "pfam:PF01180",
      "entity_text" : "dihydroorotate dehydrogenase",
      "entity_type" : "family"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q99707",
      "entity_text" : "MS",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Teriflunomide is a once-daily oral immunomodulatory disease modifying therapy approved for relapsing remitting (RR) MS that selectively and reversibly inhibits dihydroorotate dehydrogenase, a key mitochondrial enzyme in the de novo pyrimidine synthesis pathway, thus reducing the proliferation of activated T and B lymphocytes through the arrest of the cell cycle in the S phase.",
  "reading_complete" : "2020-07-28T15:03:57Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T15:03:14Z",
  "trigger" : "inhibits",
  "evidence" : [ "MS that selectively and reversibly inhibits dihydroorotate dehydrogenase" ],
  "pmc_id" : "7361089",
  "score" : 0
}